RAS

Events

Partner Content

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible.

News

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.